{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:35:04Z","timestamp":1768808104648,"version":"3.49.0"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1093\/ckj\/sfy066","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T03:29:15Z","timestamp":1529465355000},"page":"338-347","source":"Crossref","is-referenced-by-count":22,"title":["Atypical hemolytic uremic syndrome: a syndrome in need of clarity"],"prefix":"10.1093","volume":"12","author":[{"given":"Bruce E","family":"Berger","sequence":"first","affiliation":[{"name":"School of Medicine, Case Western Reserve University, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"2019053109302812200_sfy066-B1","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood"},{"key":"2019053109302812200_sfy066-B2","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"Tsai","year":"1996","journal-title":"Blood"},{"key":"2019053109302812200_sfy066-B3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"2019053109302812200_sfy066-B4","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"2019053109302812200_sfy066-B5","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B6","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: state of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"key":"2019053109302812200_sfy066-B8","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"2019053109302812200_sfy066-B9","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B10","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2019053109302812200_sfy066-B11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizimab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"2019053109302812200_sfy066-B12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizimab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019053109302812200_sfy066-B13","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"2019053109302812200_sfy066-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ckj\/sfu116","article-title":"Malignant hypertension with thrombotic microangiopathy and persistent acute kidney injury (AKI)","volume":"7","author":"Nzerue","year":"2014","journal-title":"Clin Kidney J"},{"key":"2019053109302812200_sfy066-B15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic hemolysis and renal failure in malignant hypertension","volume":"45","author":"van den Born","year":"2005","journal-title":"Hypertension"},{"key":"2019053109302812200_sfy066-B16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1291\/hypres.31.479","article-title":"Renal thrombotic microangiopathies induced by severe hypertension","volume":"31","author":"Zhang","year":"2008","journal-title":"Hypertens Res"},{"key":"2019053109302812200_sfy066-B17","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2215\/CJN.00860115","article-title":"Drug-induced glomerular disease: direct cellular injury","volume":"10","author":"Markowitz","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B18"},{"key":"2019053109302812200_sfy066-B19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"2019053109302812200_sfy066-B20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1353\/pbm.1980.0036","article-title":"A war with the molecules: Louis Pillemer and the history of properdin","volume":"100","author":"Ratnoff","year":"1980","journal-title":"Perspect Biol Med"},{"key":"2019053109302812200_sfy066-B21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4049\/jimmunol.100.1.142","article-title":"Properties of highly purified human properdin","volume":"100","author":"Ensky","year":"1968","journal-title":"J Immunol"},{"key":"2019053109302812200_sfy066-B22","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The central role of the alternative complement pathway in human disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J Immunol"},{"key":"2019053109302812200_sfy066-B23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00251-006-0142-1","article-title":"Genomic view of the evolution of the complement system","volume":"58","author":"Nonaka","year":"2006","journal-title":"Immunogenetics"},{"key":"2019053109302812200_sfy066-B24","first-page":"21","article-title":"The complement C3 protein family in invertebrates","volume":"8","author":"Nonaka","year":"2011","journal-title":"Invert Surviv J"},{"key":"2019053109302812200_sfy066-B25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/adc.51.2.91","article-title":"Defective opsonization: a common immunity deficiency","volume":"51","author":"Soothill","year":"1976","journal-title":"Arch Dis Child"},{"key":"2019053109302812200_sfy066-B26","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.154.3.856","article-title":"Formation of the initial C3 convertase of the alternative complement pathway","volume":"154","author":"Pangburn","year":"1981","journal-title":"J Exp Med"},{"key":"2019053109302812200_sfy066-B27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ajhg.2011.05.011","article-title":"Disease-causing mutations in genes of the complement system","volume":"88","author":"Degn","year":"2011","journal-title":"Am J Hum Genet"},{"key":"2019053109302812200_sfy066-B28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-065X.1998.tb01249.x","article-title":"The phylogeny and evolution of the thioester bond-containing proteins C3, C4 and \u03b12-macroglobulin","volume":"166","author":"Dodds","year":"1998","journal-title":"Immunol Rev"},{"key":"2019053109302812200_sfy066-B29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/biom2010046","article-title":"Factor H: a complement regulator in health and disease, and a mediator of cellular interactions","volume":"2","author":"Kopp","year":"2012","journal-title":"Biomolecules"},{"key":"2019053109302812200_sfy066-B30","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1074\/jbc.M508928200","article-title":"The role of properdin in the assembly of the alternative pathway C3 convertases of complement","volume":"281","author":"Hourcade","year":"2006","journal-title":"J Biol Chem"},{"key":"2019053109302812200_sfy066-B31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.imbio.2012.07.016","article-title":"Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy","volume":"217","author":"Ricklin","year":"2012","journal-title":"Immunobiology"},{"key":"2019053109302812200_sfy066-B32","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.4049\/jimmunol.153.5.2213","article-title":"Antibody-mediated complement activation on nucleated cells: a quantitative analysis of the individual reaction steps","volume":"153","author":"Ollert","year":"1994","journal-title":"J Immunol"},{"key":"2019053109302812200_sfy066-B33","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1084\/jem.20070664","article-title":"Complement factor H and the hemolytic uremic syndrome","volume":"204","author":"Atkinson","year":"2007","journal-title":"J Exp Med"},{"key":"2019053109302812200_sfy066-B34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.142.4.856","article-title":"Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase","volume":"142","author":"Fearon","year":"1975","journal-title":"J Exp Med"},{"key":"2019053109302812200_sfy066-B35","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.179.4.2600","article-title":"Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly","volume":"179","author":"Spitzer","year":"2007","journal-title":"J Immunol"},{"key":"2019053109302812200_sfy066-B36","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizimab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"2019053109302812200_sfy066-B37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molimm.2014.07.004","article-title":"Complement nomenclature 2014","volume":"61","author":"Kemper","year":"2014","journal-title":"Mol Immunol"},{"key":"2019053109302812200_sfy066-B38","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","article-title":"Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway","volume":"120","author":"Krisinger","year":"2012","journal-title":"Blood"},{"key":"2019053109302812200_sfy066-B39","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1073\/pnas.73.9.3268","article-title":"Control of the amplification convertase by the plasma protein \u03b21H","volume":"73","author":"Weiler","year":"1976","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019053109302812200_sfy066-B40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2005.10.014","article-title":"Membrane complement regulatory proteins","volume":"118","author":"Kim","year":"2006","journal-title":"Clin Immunol"},{"key":"2019053109302812200_sfy066-B41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetics studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"key":"2019053109302812200_sfy066-B42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1681\/ASN.2013121339","article-title":"A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1\/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation","volume":"26","author":"Valoti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B44","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"2019053109302812200_sfy066-B45","first-page":"21","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc NY Pathol Sci"},{"key":"2019053109302812200_sfy066-B46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/adc.53.3.255","article-title":"Familial haemolytic syndrome","volume":"53","author":"Edelsten","year":"1978","journal-title":"Arch Dis Child"},{"key":"2019053109302812200_sfy066-B47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"2019053109302812200_sfy066-B48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldl004","article-title":"Atypical haemolytic uraemic syndrome","volume":"77\u201378","author":"Kavanagh","year":"2006","journal-title":"Br Med Bull"},{"key":"2019053109302812200_sfy066-B49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"2019053109302812200_sfy066-B50","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"2019053109302812200_sfy066-B51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fped.2014.00097","article-title":"Extra-renal manifestations complement-mediated thrombotic microangiopathy","volume":"2","author":"Hofer","year":"2014","journal-title":"Front Pediatr"},{"key":"2019053109302812200_sfy066-B52","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B53","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"2019053109302812200_sfy066-B54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrneph.2014.250","article-title":"Podocyte dysfunction in atypical haemolytic uraemic syndrome","volume":"11","author":"Noris","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"2019053109302812200_sfy066-B55","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","article-title":"Complement mutations in diacylglycerol kinase-\u03b5-associated atypical hemolytic uremic syndrome","volume":"9","author":"Sanchez Chinchilla","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B56","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGK\u03b5 induces endothelial cell activation and death independently of complement activation","volume":"125","author":"Bruneau","year":"2015","journal-title":"Blood"},{"key":"2019053109302812200_sfy066-B57","first-page":"417","article-title":"A rare cause of the pulmonary-renal syndrome: a case of atypical haemolytic-uraemic syndrome complicated by pulmonary hemorrhage","volume":"6","author":"Derebail","year":"2008","journal-title":"NDT Plus"},{"key":"2019053109302812200_sfy066-B58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nrneph.2013.280","article-title":"Cardiovascular complications in atypical haemolytic uraemic syndrome","volume":"10","author":"Noris","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"2019053109302812200_sfy066-B59","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/gfq160","article-title":"Myocardial infarction is a complication of factor H-associated atypical HUS","volume":"25","author":"Sall\u00e9e","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2019053109302812200_sfy066-B60","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0009922811412942","article-title":"Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension","volume":"52","author":"Totina","year":"2013","journal-title":"Clin Pediatr"},{"key":"2019053109302812200_sfy066-B61","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.ajkd.2013.09.020","article-title":"Skin involvement in atypical hemolytic uremic syndrome","volume":"63","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2019053109302812200_sfy066-B62","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.3928\/01913913-20140923-03","article-title":"Recurrent ocular involvement in pediatric atypical hemolytic uremic syndrome","volume":"51","author":"Zheng","year":"2014","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2019053109302812200_sfy066-B63","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-007-0540-0","article-title":"Ocular involvement in hemolytic uremic syndrome due to factor H deficiency\u2014are there therapeutic consequences?","volume":"22","author":"Larakeb","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"2019053109302812200_sfy066-B64","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/eye.2013.111","article-title":"Resolution of ocular involvement with systemic eculizimab in atypical hemolytic-uremic syndrome","volume":"27","author":"David","year":"2013","journal-title":"Eye"},{"key":"2019053109302812200_sfy066-B65","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-03-492421","article-title":"Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome","volume":"122","author":"Feng","year":"2013","journal-title":"Blood"},{"key":"2019053109302812200_sfy066-B66","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizimab in the treatment of refractory idiopathic thrombotic thromobocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haemotol"},{"key":"2019053109302812200_sfy066-B67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrneph.2014.38","article-title":"Renal involvement in antiphospholipid syndrome","volume":"10","author":"Sciascia","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"2019053109302812200_sfy066-B68","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0046-8177(92)90127-O","article-title":"A congenital anomaly of vitamin B12 metabolism: a study of three cases","volume":"23","author":"Russo","year":"1992","journal-title":"Hum Pathol"},{"key":"2019053109302812200_sfy066-B69","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizimab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med"},{"key":"2019053109302812200_sfy066-B70","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B71","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizimab in secondary atypical hemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Doal Transplant"},{"key":"2019053109302812200_sfy066-B72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizimab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2019053109302812200_sfy066-B73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.amjms.2016.05.003","article-title":"The alternative pathway of complement and the evolving clinical-pathophysiological spectrum of atypical hemolytic uremic syndrome","volume":"352","author":"Berger","year":"2016","journal-title":"Am J Med Sci"},{"key":"2019053109302812200_sfy066-B74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizimab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B75","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2215\/CJN.08520814","article-title":"Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome","volume":"10","author":"Mele","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019053109302812200_sfy066-B76","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/BSR20140117","article-title":"New functional and structural insights from updated mutational databases for complement factor H, factor I, membrane cofactor protein and C3","volume":"34","author":"Rodriguez","year":"2014","journal-title":"Biosci Rep"},{"key":"2019053109302812200_sfy066-B77","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ekir.2017.12.013","article-title":"Renal thrombotic microangiopathy after hematopoietic stem cell transplantation: involvement of chronic graft-versus-host disease","volume":"3","author":"Mii","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2019053109302812200_sfy066-B78","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"2019053109302812200_sfy066-B79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1269","article-title":"The dark side of C5a in sepsis","volume":"4","author":"Ward","year":"2004","journal-title":"Nature Rev Immunol"},{"key":"2019053109302812200_sfy066-B80","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizimab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"2019053109302812200_sfy066-B81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights from the use in clinical practice of eculizimab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2019053109302812200_sfy066-B82","first-page":"3471","volume-title":"Blood","author":"Li","year":"2015"},{"key":"2019053109302812200_sfy066-B83","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizimab in atypical hemolytic uremic syndrome from 2-year extension of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"2019053109302812200_sfy066-B84","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizimab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"2019053109302812200_sfy066-B85","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizimab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2019053109302812200_sfy066-B86","first-page":"310","article-title":"Current evidence on the discontinuation of eculizimab in patients with atypical hemolytic uremic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"key":"2019053109302812200_sfy066-B87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2017.06.007","article-title":"Alternative complement pathway hemolytic assays reveal incomplete blockade in patients treated with eculizimab","volume":"183","author":"Puissant-Lubrano","year":"2017","journal-title":"Clin Immunol"},{"key":"2019053109302812200_sfy066-B88"},{"key":"2019053109302812200_sfy066-B89","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2013","journal-title":"Kidney Int"},{"key":"2019053109302812200_sfy066-B90","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"key":"2019053109302812200_sfy066-B91","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/TP.0000000000000267","article-title":"A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizimab","volume":"98","author":"Bakhtar","year":"2014","journal-title":"Transplantation"},{"key":"2019053109302812200_sfy066-B92","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizimab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"key":"2019053109302812200_sfy066-B93","first-page":"704371","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizimab: a case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol"},{"key":"2019053109302812200_sfy066-B94","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizimab in acute recurrence of thrombotic microangiopathy after renal transplantation","volume":"11","author":"Hadaya","year":"2011","journal-title":"Am J Transplant"},{"key":"2019053109302812200_sfy066-B95","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizimab in a patient with immunoabsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine"},{"key":"2019053109302812200_sfy066-B96","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizimab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2019053109302812200_sfy066-B97","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/annrheumdis-2015-eular.3587","article-title":"Response to eculizimab in the antiphospholipid antibody syndrome","volume":"74","author":"Zapantis","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2019053109302812200_sfy066-B98","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizimab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"2019053109302812200_sfy066-B99","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/12\/3\/338\/28752493\/sfy066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T07:46:27Z","timestamp":1693727187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/12\/3\/338\/5062946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":99,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,7,31]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfy066","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2018,7,31]]}}}